MA37324A1 - Composition pharmaceutique pour le traitement de l'incontinence urinaire et de l'énurésie - Google Patents

Composition pharmaceutique pour le traitement de l'incontinence urinaire et de l'énurésie

Info

Publication number
MA37324A1
MA37324A1 MA37324A MA37324A MA37324A1 MA 37324 A1 MA37324 A1 MA 37324A1 MA 37324 A MA37324 A MA 37324A MA 37324 A MA37324 A MA 37324A MA 37324 A1 MA37324 A1 MA 37324A1
Authority
MA
Morocco
Prior art keywords
enuresis
treatment
pharmaceutical composition
proportion
composition
Prior art date
Application number
MA37324A
Other languages
English (en)
Inventor
Agustí Juan Carlos Llobregat
Original Assignee
Laboratec S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratec S L filed Critical Laboratec S L
Publication of MA37324A1 publication Critical patent/MA37324A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une composition pharmaceutique pour le traitement de l'incontinence urinaire et/ou de l'énurésie, comprenant au moins un mélange de flavonoïdes, en proportion comprise entre 0,5% et 20% en poids, de tanins condensés ou de pro-anthocyanidines, en proportion comprise entre 2% et 20% en poids, et d'acide gamma-aminobutyrique (gaba), en proportion comprise entre 0,3% et 60% en poids, sur le total de la composition. Ladite composition comprend en outre au moins 50% d'un extrait d'humulus lupulus. La présente invention concerne également l'utilisation de ladite composition pour l'obtention d'un médicament pour traiter l'incontinence et/ou l'énurésie, notamment l'énurésie chez les enfants, ainsi que chez les adultes ou les personnes âgées souffrant de pertes d'urine telles l'incontinence de stress ou d'urgence.
MA37324A 2012-02-15 2013-01-22 Composition pharmaceutique pour le traitement de l'incontinence urinaire et de l'énurésie MA37324A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201230242A ES2423254B1 (es) 2012-02-15 2012-02-15 Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis
PCT/ES2013/070022 WO2013121061A1 (fr) 2012-02-15 2013-01-22 Composition pharmaceutique pour le traitement de l'incontinence urinaire et de l'énurésie

Publications (1)

Publication Number Publication Date
MA37324A1 true MA37324A1 (fr) 2016-03-31

Family

ID=48983578

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37324A MA37324A1 (fr) 2012-02-15 2013-01-22 Composition pharmaceutique pour le traitement de l'incontinence urinaire et de l'énurésie

Country Status (20)

Country Link
US (1) US9272011B2 (fr)
EP (1) EP2815755A4 (fr)
JP (1) JP6203761B2 (fr)
KR (1) KR20140127874A (fr)
CN (1) CN104254338B (fr)
AU (1) AU2013220284A1 (fr)
BR (1) BR112014020154A8 (fr)
CA (1) CA2864426A1 (fr)
CL (1) CL2014002128A1 (fr)
CO (1) CO7141408A2 (fr)
CR (1) CR20140419A (fr)
EA (1) EA028184B1 (fr)
ES (1) ES2423254B1 (fr)
IL (1) IL233978A0 (fr)
MA (1) MA37324A1 (fr)
MX (1) MX367671B (fr)
PE (1) PE20142324A1 (fr)
PH (1) PH12014501823A1 (fr)
WO (1) WO2013121061A1 (fr)
ZA (1) ZA201406668B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110339316B (zh) * 2019-08-09 2021-09-21 河南中医药大学 一种治疗中风后尿失禁的中药
CN116036153B (zh) * 2023-02-22 2023-09-26 深圳市儿童医院 啤酒花提取物在制备用于治疗或者预防抑郁症、抑郁症并发症、焦虑症的产品中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9137091A (en) 1990-11-27 1992-06-25 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
RU94046105A (ru) 1992-05-20 1997-06-20 Нортвестерн Юниверсити (Us) АНАЛОГИ γ -АМИНОМАСЛЯНОЙ КИСЛОТЫ И L-ГЛУТАМИНОВОЙ КИСЛОТЫ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
JP2002541198A (ja) * 1999-04-08 2002-12-03 ワーナー−ランバート・カンパニー 失禁の治療法
FR2823672B1 (fr) * 2001-04-23 2004-03-12 Berkem Sa Extraits de houblon et leur utilisation dans la preparation d'un medicament ayant des proprietes oestrogenes
JP2003088335A (ja) * 2001-09-14 2003-03-25 Pharmafoods Kenkyusho:Kk 排尿機能改善用食品組成物及びそれを含有する飲食品
GB0306568D0 (en) * 2003-03-21 2003-04-30 Unilever Plc Compositions of natural products and use thereof
NZ526350A (en) * 2003-06-09 2004-10-29 A Anti-aging compositions comprising an amino acid, vitamin B complex, metal salt and an amino alcohol
CN1867327A (zh) * 2003-09-11 2006-11-22 什诺波特有限公司 使用gaba类似物的前药治疗和/或预防尿失禁
NZ546138A (en) * 2003-10-09 2009-12-24 Pacific Arrow Ltd Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
US20070116839A1 (en) * 2005-11-23 2007-05-24 The Coca-Cola Company High-Potency Sweetener Composition With C-Reactive Protein Reducing Substance and Compositions Sweetened Therewith
EP1889612A3 (fr) * 2006-07-24 2008-03-19 Jan Kees Piet Bruinstroop Methode pour commander la miction
US20090180999A1 (en) * 2008-01-11 2009-07-16 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections using cranberry derivative and d-mannose composition

Also Published As

Publication number Publication date
KR20140127874A (ko) 2014-11-04
US20150044308A1 (en) 2015-02-12
IL233978A0 (en) 2014-09-30
MX367671B (es) 2019-08-30
CR20140419A (es) 2014-11-28
US9272011B2 (en) 2016-03-01
WO2013121061A1 (fr) 2013-08-22
CA2864426A1 (fr) 2013-08-22
BR112014020154A8 (pt) 2017-07-11
PH12014501823A1 (en) 2014-11-24
AU2013220284A1 (en) 2014-09-25
PE20142324A1 (es) 2015-01-16
JP2015507002A (ja) 2015-03-05
CL2014002128A1 (es) 2015-03-13
CN104254338A (zh) 2014-12-31
CN104254338B (zh) 2019-05-31
ZA201406668B (en) 2016-05-25
EA201491437A1 (ru) 2015-06-30
BR112014020154A2 (fr) 2017-06-20
ES2423254A1 (es) 2013-09-18
CO7141408A2 (es) 2014-12-12
EA028184B1 (ru) 2017-10-31
EP2815755A1 (fr) 2014-12-24
JP6203761B2 (ja) 2017-09-27
EP2815755A4 (fr) 2015-08-05
MX2014009464A (es) 2014-11-12
ES2423254B1 (es) 2014-03-26

Similar Documents

Publication Publication Date Title
MA30914B1 (fr) Dihydropyrazolones substituees utilisees dans le traitement de maladies cardiovasculaires et hematologiques.
BR0308290A (pt) Tratamento e prevenção de distúrbios inflamatórios
MA35039B1 (fr) Dérivés ramifiés de l'acide 3-phénylpropionique et leur utilisation
MA32226B1 (fr) Compositions et leurs procedes de preparation et d'utilisation
MA35132B1 (fr) 4-aryl-n-phényl-1,3,5-triazine-2- amines contenant un groupe sulfoximine
MA34721B1 (fr) Acides carboxyliques 1-benzylcycloalkyle substitués et leur utilisation
NZ612315A (en) Compositions for immunising against staphylococcus aureus
MA34765B1 (fr) Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci
MEP8509A (en) Combination treatment for diabetes mellitus
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA33488B1 (fr) Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn
MA33123B1 (fr) 2-acetamido-5-aryl-1,2,4-triazolones substitues et leur utilisation
MA33449B1 (fr) Antigènes recombinants du vrs
BRPI0516132A (pt) compostos, composição destes, método de antagonização de uma ou mais proteases aspárticas e método para tratar ou melhorar um distúrbio mediado por protease aspártica
MA32131B1 (fr) Antagonistes aminoalkylbiphényle n, n' disubstitués des récepteurs d2 de la prostaglandine
FR2949044B1 (fr) Composition comprenant une fraction d'insaponifiable
MA33302B1 (fr) 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale
WO2005074986A3 (fr) Especes bioactive capables d'interferer avec un complexe toxine-antitoxine microbien et procedes d'evaluation et d'utilisation de ladite espece bioactive
Pei et al. Response of human periodontal ligament cells to baicalin
Shwetank et al. Infection of human endothelial cells by Japanese encephalitis virus: increased expression and release of soluble HLA-E
Wu et al. Effects of epigallocatechin-3-gallate and acyclovir on herpes simplex virus type 1 infection in oral epithelial cells
WO2006130426A3 (fr) Modulateurs de l'activite des ccr-5
MA37324A1 (fr) Composition pharmaceutique pour le traitement de l'incontinence urinaire et de l'énurésie
Lee et al. Anti-inflammatory effects of bamboo salt and sodium fluoride in human gingival fibroblasts–An in vitro study
Kim et al. Naringenin stimulates osteogenic/odontogenic differentiation and migration of human dental pulp stem cells